Loading market dashboard
STAAR Surgical Company
STAAHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
STAAR Surgical supplies implantable lenses for vision correction, serving ophthalmic surgeons and clinics globally with proprietary tech.
On May 28, 2026, Staar Surgical Co (STAA) shares fell 7.3% to a current price of $29.08. This decline comes amidst a volatile trading period, as the stock has e
STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026 Format: Meetings and Webcast Fireside Chat Details: Investor meeting participation is by invitation only from the sponsoring brokerage firm. Webcas.
STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China's market rebound, normalized inventory, and rapid EVO+ ICL adoption drove topline strength, while disciplined OpEx and manufacturing efficiency boosted margins to 73.6%. STAA is benefiting from a structural shift toward lens-based refractive surgery, gaining U.S. share despite a shrinking laser market and expanding its addressable market via FDA approval.
Staar Surgical shares catapulted Thursday after the eye surgery outlet obliterated first-quarter profit expectations.
STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript
STAAR Surgical NASDAQ: STAA said its first quarter of 2026 marked a sharp rebound in sales and profitability, driven by strong demand in China, continued growth in the U.S. and tighter cost controls following a difficult 2025.
While the top- and bottom-line numbers for Staar Surgical (STAA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Staar Surgical (STAA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to a loss of $0.52 per share a year ago.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results in combination with a shareholder letter for the first quarter ended April 3, 2026, on Wednesday, May 13, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and bus.
On May 01, 2026, Staar Surgical Co (STAA) shares rose 3.1% today, bringing the current price to $27.19. Over the past 52 weeks, the stock has fluctuated between
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STAAR Surgical (STAA) stock surged more than 25% on Thursday after the ophthalmic implant maker projected first-quarter net sales would top $90 million, more th
The major indexes are pulling back after yesterday's ceasefire-related surge
STAAR Surgical Company has seen a dramatic valuation reset, now trading at a $1bn market cap after failed acquisition talks and underwhelming US growth. Q1 2026 net sales are expected to exceed $90m, driven by a strong rebound in China and signaling potential for record annual revenues. Despite operational challenges and competitive pressures, STAA's proprietary Collamer lens and expanded US indications provide incremental growth opportunities.
STAAR Surgical (STAA) expects Q1 net sales to exceed $90M, more than doubling year-over-year, driven primarily by China and double-digit growth in the Americas. Disney plans 1,000 job cuts in marketing overhaul under new CEO.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quarter ended April 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement because it expects to be interacting with members of the investment community, as well as with surgeons and other members of t.
Staar Surgical (STAA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Defender Capital LLC. purchased a new stake in shares of STAAR Surgical Company (NASDAQ: STAA) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 668,222 shares of the medical instruments supplier's stock, valued at approximately $15,429,000. STAAR Surgical accounts for
STAAR Surgical Company (NASDAQ: STAA - Get Free Report) Director Broadwood Partners, L.P. purchased 316,017 shares of the business's stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average price of $18.61 per share, with a total value of $5,881,076.37. Following the completion of the purchase, the director owned
STAAR Surgical Company (NASDAQ: STAA - Get Free Report) Director Broadwood Partners, L.P. purchased 299,432 shares of the business's stock in a transaction on Thursday, March 12th. The shares were purchased at an average price of $18.12 per share, with a total value of $5,425,707.84. Following the completion of the purchase, the director owned 15,807,825 shares
